For example, selumetinib (a MEK inhibitor) and vemurafenib and dabrafenib (mutant BRAF inhibitors) are clinically beneficial in thyroid cancer patients with advanced metastatic disease. This evidence concerns the gene MAP2K7 and thyroid gland carcinoma.